|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin speaks with several leading companies to explore chemical and physical modification versus formulation development, and new technologies and techniques for improving bioavailability and solubility.
|
|
|
Sven Stegemann, PhD, Matt Shaffer, Samantha Saville, and Jaspreet Arora, PhD, believe as pediatric formulations are expected to continue as a core research area in pharmaceutical technology, MP technologies have the potential to play a key role.
|
|
|
Jim Huang, PhD, and Edward Orton, PhD, say it is critically important CROs or CDMOs that support discovery and preclinical research have the requisite preformulation, formulation, and biopharmaceutics expertise as well as the proprietary methodologies to develop formulations from small quantities of drug candidates for different routes of administration.
|
|
|
Michael J. LaBarre, PhD, discusses how the ENHANZE drug delivery technology has the potential to improve the pharmacokinetic profiles of co-administered drugs through increased dispersion, absorption, and bioavailability.
|
|
|
|
|
|
|
|
|

Frontida BioPharm, Inc. is a leading provider of product development and manufacturing services for both small and large biotech, pharmaceutical, and consumer health companies. Combining the rich heritage of resources from URL/Mutual Pharmaceuticals in Philadelphia, PA, and Aurora, IL, with the development expertise from Frontage Laboratories and the region’s best pharmaceutical companies, Frontida is helping our partners reach the market faster, ensuring robust product performance and on-time supply of clinical and commercial products. Click here for more.
|
|
|
|
|
|
 |
|
AptarGroup, Inc. recently announced it has acquired Noble International, a leader in drug delivery training devices and patient onboarding. This acquisition furthers Aptar’s strategy to broaden……
|
|
 |
|
Flexion Therapeutics, Inc. recently announced clearance of the company’s Investigational New Drug (IND) application for FX201 in knee osteoarthritis.
|
|
 |
|
Cycle Pharmaceuticals Ltd. has recently signed an agreement with Catalent, Inc. to develop innovative formulations targeting rare disease patients.
|
|
 |
|
Ashland recently announced the launch of three new pharmaceutical solutions, Plasdone S630 Ultra, Benecel XR and XRF, and Viatel bioresorbable polymers. Ashland is expanding its portfolio to meet formulators’ growing needs….
|
|
|
|
|
Upcoming eNewsletter Features:
Nov 13 – Prefilled Syringes
Nov 20 – Analytical Testing
|
|
|
|
|
|
|
|